Finance
FluINsure maker announces closing of US$100 million bought deal financing
Published in Vaccine Weekly, November 26th, 2003
ID Biomedical sold a total of 5,800,000 units at a price of US$17.37 per unit for total gross proceeds of US$100,746,000. Each unit consists of one common share and one-half of one common share purchase warrant. Subject to adjustment, each whole warrant entitles the holder thereof to purchase an additional common share at the price of US$25.00 for a period of 4 years after the closing date of the offering.
The net proceeds of the offering will be used for the clinical and manufacturing development of ID Biomedical's FluINsure and StreptAvax vaccines, working...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
Source: Vaccine Weekly (2003-11-26)
More Articles from Vaccine Weekly
- Syphilis
Treponema pallidum repeat protein K antibodies protect against syphilis - Vaccine Delivery
Particle-mediated method for delivery of vaccines into epidermis developed - Cancer Vaccine
Converting tumors to Ii protein-negative phenotype causes tumor shrinkage - HIV/AIDS Vaccine
New gene-based approaches for AIDS vaccine reviewed - Prion Disease
Prion protein-derived peptide prolongs survival of mice exposed to scrapie - Vector Development
Poxviruses show promise as vaccine vectors - More from this issue of Vaccine Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
